Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M175Revenue $M0.3Net Margin (%)-15,828.3Z-Score0.3
Enterprise Value $M72.4EPS $-1.4Operating Margin %-9,198.0F-Score3
P/E(ttm))0Cash Flow Per Share $-0.9Pre-tax Margin (%)-15,828.0Higher ROA y-yN
Price/Book2.110-y EBITDA Growth Rate %-12.9Quick Ratio4.7Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %9.4Current Ratio4.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-114.4Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-445.4Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M55.8ROI % (ttm)-43.5Gross Margin Increase y-yN

Gurus Latest Trades with CYTR

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CYTRGeorge Soros 2014-06-30 Sold Out $2.92 - $5.31
($3.79)
$ 3.14-17%Sold Out0
CYTRGeorge Soros 2014-03-31 Buy $3.18 - $8.08
($5.96)
$ 3.14-47%New holding, 81800 sh.81,800
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CYTR is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
CYTR George Soros 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


CYTR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Patterson Scott Bradford10% Owner 2013-12-03Buy284,979$2.4428.69view
Patterson Scott Bradford10% Owner 2013-11-07Buy50,000$2.0652.43view
Patterson Scott Bradford10% Owner 2013-04-01Buy4,083$2.716.3view
Patterson Scott Bradford10% Owner 2013-03-20Buy3,980$2.6120.31view
Patterson Scott Bradford10% Owner 2013-03-20Buy35,520$2.5821.71view
Patterson Scott Bradford10% Owner 2013-03-13Buy55,360$2.6717.6view
Patterson Scott Bradford10% Owner 2012-10-22Buy180,000$2.5125.1view
Patterson Scott Bradford10% Owner 2012-10-18Buy1,200,000$2.525.6view
Patterson Scott Bradford10% Owner 2012-06-28Buy44,824$5.14-38.91view
Patterson Scott Bradford10% Owner 2012-06-25Buy27,462$5-37.2view

Press Releases about CYTR :

Quarterly/Annual Reports about CYTR:

News about CYTR:

Articles On GuruFocus.com
Weekly CFO Buys Highlight: CYTR, API, CLGX, PLBC, ARTC Mar 05 2012 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CFO Buys Highlight: CYTR, PZZI, AGYS, PLBC Feb 27 2012 
CytRx Corp. Reports Operating Results (10-K) Mar 11 2011 
CytRx Corp. Reports Operating Results (10-Q) Nov 08 2010 
CytRx Corp. Reports Operating Results (10-Q) Aug 09 2010 
CytRx Corp. Reports Operating Results (10-Q) May 06 2010 
CytRx Corp. Reports Operating Results (10-Q) Nov 09 2009 
CytRx Reports 2009 Second Quarter Financial Results Aug 10 2009 
CytRx Corp. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
CYTRX CORP Financials Aug 19 2014
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into CytRx... Aug 11 2014
Oral Presentation of CytRx’s Aldoxorubicin Phase 2b Clinical Trial in Soft Tissue Sarcoma... Aug 07 2014
Oral Presentation of CytRx’s Aldoxorubicin Phase 2b Clinical Trial in Soft Tissue Sarcoma... Aug 07 2014
CytRx Reports 2014 Second Quarter Financial Results Aug 06 2014
CYTRX CORP Files SEC form 10-Q, Quarterly Report Aug 06 2014
CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 06 2014
CytRx Reports 2014 Second Quarter Financial Results Aug 06 2014
Former Louisiana Attorney General and KSF Announce Appointment as Lead Counsel in CytRx Securities... Aug 05 2014
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into CytRx... Jul 09 2014
CytRx Added to Russell 3000® and Russell 2000® Indexes Jun 30 2014
CYTRX CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 27 2014
Five Analyst Stock Picks With 100% or More Implied Upside Jun 07 2014
Celldex: The Race Leader In Glioblastoma Multiforme May 29 2014
CytRx to Present at the Jefferies 2014 Global Healthcare Conference May 29 2014
CytRx's aldoxorubicin for sarcoma shows positive Phase 2b results May 28 2014
CytRx Highlights Aldoxorubicin Data from its Global Phase 2b Clinical Trial in First-Line Soft... May 28 2014
CYTRX 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and... May 09 2014

Add Notes, Comments or Ask Questions

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide